NasdaqGS - Delayed Quote • USD
Relmada Therapeutics, Inc. (RLMD)
At close: April 24 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director | 1.79M | -- | 1960 |
| Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer | 1.01M | -- | 1964 |
| Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer | 995.03k | -- | 1965 |
| Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer | -- | -- | 1962 |
| Ms. Gina DiGuglielmo | VP & Head of Clinical Operations | -- | -- | -- |
| Dr. Marco Pappagallo M.D. | Chief Clinical Officer | -- | -- | 1959 |
| Mr. John Hixon | Head of Commercial | -- | -- | -- |
| Dr. Andrew Cutler | Senior Clinical Development Advisor | -- | -- | -- |
| Dr. Richard M. Mangano | Consultant | -- | -- | 1950 |
Relmada Therapeutics, Inc.
2222 Ponce de Leon Boulevard
Floor 3
Coral Gables, FL 33134
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 20
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Corporate Governance
Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 09, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 19, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 11, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 09, 2024 - May 13, 2024
Relmada Therapeutics, Inc. Earnings Call
Related Tickers
APLT Applied Therapeutics, Inc.
4.3100
-3.36%
AVTE Aerovate Therapeutics, Inc.
21.20
-8.70%
INZY Inozyme Pharma, Inc.
4.4000
0.00%
PCVX Vaxcyte, Inc.
60.30
-0.95%
NVCT Nuvectis Pharma, Inc.
6.71
+1.82%
RPHM Reneo Pharmaceuticals, Inc.
1.6800
+0.30%
GHRS GH Research PLC
11.08
-1.95%
SLRN Acelyrin, Inc.
4.5700
-0.65%
PEPG PepGen Inc.
11.83
+0.94%
IOBT IO Biotech, Inc.
1.4600
-0.68%